Evaluation of disease risk comorbidity index after allogeneic stem cell transplantation in a cohort with patients transplanted with in-vitro partially T-cell depleted grafts.

Allogeneic stem cell transplantation (HSCT) is the only curative treatment for most haematological malignancies. Outcomes of HSCT mainly depend on disease characteristics and patient conditions. Tools that help physicians to predict outcomes are important to determine which patient would most likely benefit of HSCT. Over the last decades, several prognostic scores have been developed. The Disease Risk Index (DRI)1, 2, that include type and status of disease at transplant time is predictive of overall survival (OS), but does not integrate patient's comorbidities and overall conditions.

Source: Biology of Blood and Marrow Transplantation - September 23, 2020 Category: Hematology Authors: Yan Beauverd, Sarah Morin, Mitja Nabergoj, Caroline Stephan, Carmen De Ramon Ortiz, Anne-Claire Mamez, Elif Mahne, Anna Petropoulou, Federica Giannotti, Christian Ayer, Benjamin Bruno, Laura Bounaix, Maria Anastasiou, Maria Mappoura, Thien-An Tran, Stavro Source Type: research